CJC-1295

Limited controlled human pharmacology.



Guide prepared November 13, 2026 · profile review dates retained

KEEP IN MIND Evidence applies to the studied formulation, route, population and outcome—not every product sharing a name.

01 What is it?

CJC-1295 is an experimental long-acting growth-hormone-releasing hormone analog. Small human studies measured increases in growth hormone and IGF-1, rather than establishing benefits for recovery, athletic performance, or healthy aging. [1]

02 Potential benefits

Small controlled studies demonstrated prolonged stimulation of growth hormone and IGF-1. Those pharmacodynamic findings do not establish meaningful clinical benefit for wellness or athletic goals. [1]

03 Evidence & its limits

A measurable hormone increase is not a demonstrated improvement in health or function. FDA describes limited clinical data and concerns involving immunogenicity and impurities, and identifies serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilation. [1]

04 Risks & unknowns

FDA identifies limited clinical data, potential immunogenicity and peptide-impurity concerns. FDA has identified serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction. Long-term safety and clinical outcomes remain uncertain. [1]

05 Status & scope

Not FDA-approved. Small controlled hormone-response studies do not establish recovery, athletic performance or healthy-aging benefits. [1]

06 The question to ask

Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.

SOURCES / Tap a reference to open

[1] Full evidence record, references and review dates
[2] FDA compounding safety assessment
[3] CJC-1295 controlled human pharmacology, 2006
[4] Human pharmacology study / JCEM

Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.